Federal Register / Vol. 89, No. 16 / Wednesday, January 24, 2024 / Notices 4609 

Thayer Agency, Inc., and thereby 

indirectly retain additional voting 

shares of Thayer County Bank, both of 

Hebron, Nebraska. In addition, Rebecca 

Schure, Omaha, Nebraska, to become a 

member of the Kenner Family Group, to 

retain voting shares of Thayer Agency, 

Inc., and thereby indirectly retain voting 

shares of Thayer County Bank. 

Board of Governors of the Federal Reserve 

System. 

Ann Misback, 

Secretary of the Board. 

[FR Doc. 2024–01348 Filed 1–23–24; 8:45 am] 

BILLING CODE P 

OFFICE OF GOVERNMENT ETHICS 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Electronic Public 

Financial Disclosure Extension 

Request 

AGENCY: Office of Government Ethics 

(OGE). 

ACTION: Notice and request for 

comments. 

SUMMARY: The Office of Government 

Ethics (OGE) seeks comment on the 

development of a new module allowing 

filers to request an extension of the time 

available to file a public financial 

disclosure report within its Integrity 

electronic filing system. This notice 

announces that OGE intends to submit 

this collection to the Office of 

Management and Budget (OMB) for 

approval under the Paperwork 

Reduction Act. 

DATES: Consideration will be given to all 

written comments received by March 

25, 2024. 

ADDRESSES: Comments may be 

submitted to OGE by the following 

methods: 

Email: usoge@oge.gov (Include 

reference to ‘‘Extension Module PRA 

Comment’’ in the subject line of the 

message.) 

Mail: Office of Government Ethics, 

250 E Street SW, Suite 750, Washington 

DC 20024–3249, Attention: Jennifer 

Matis, Associate Counsel. 

Instructions: Comments may be 

posted on OGE’s website, www.oge.gov. 

Sensitive personal information, such as 

account numbers or Social Security 

numbers, should not be included. 

Comments generally will not be edited 

to remove any identifying or contact 

information. 

FOR FURTHER INFORMATION CONTACT: 

Jennifer Matis at the U.S. Office of 

Government Ethics; telephone: 202– 

482–9216; TTY: 800–877–8339; Email: 

jmatis@oge.gov. 

SUPPLEMENTARY INFORMATION: 

Title: Electronic Public Financial 

Disclosure Extension Request. 

Abstract: The Integrity Public 

Financial Disclosure Extension Request 

will be a module within OGE’s Integrity 

electronic filing application. Certain 

officers and high-level employees in the 

executive branch are required to file 

public financial disclosure reports via 

the OGE Form 278e and OGE Form 278– 

T for the purpose of conflict of interest 

review and public disclosure. The form 

is also completed by individuals who 

are nominated by the President for highlevel executive branch positions 

requiring Senate confirmation and 

individuals entering into and departing 

from other public reporting positions in 

the executive branch. 

In 2014, OGE sought and received 

approval to incorporate the OGE Form 

278e into its Integrity electronic filing 

application. Integrity has been in use 

since January 1, 2015, and most public 

financial disclosure filers now use 

Integrity to file the OGE Form 278e and 

OGE Form 278–T. Although Integrity is 

primarily used by current executive 

branch federal employees, it is also used 

to file termination reports by certain 

filers who have recently left government 

service. 

The proposed module within Integrity 

will allow filers to easily request an 

extension of time to file their report. 

The module can be ‘‘turned on’’ by the 

filers’ reporting agency, or the agency 

may choose not to use it. Requests for 

extensions are currently made by calling 

or emailing the filer’s agency ethics 

official and require that the filer provide 

a reason for requesting an extension. 

The ethics official can then manually 

enter the number of days granted into 

Integrity and those days will be 

displayed on the cover page of the 

printed report, which is made public in 

accordance with 5 U.S.C. 13107. If the 

extension was granted because the filer 

is in a combat zone, the reason for the 

extension is also noted on the report. 

Once the new feature is deployed and 

an agency chooses to enable the feature, 

their filers will request an extension 

through the Integrity module. The 

electronic extension request will then be 

presented within the Integrity 

application to the appropriate ethics 

official at the employing agency. If the 

ethics official grants the request, the 

required information will automatically 

appear on the filer’s report as generated 

by the Integrity application. 

OGE believes that many agencies will 

avail themselves of the option to use the 

new module. For those that do, 

automating this process will make it 

easier for both the filer and the agency 

ethics officials and will reduce the 

chance that required information will be 

omitted from the filer’s report. The 

development of this feature has been 

ranked a high priority by the Integrity 

Advisory Council (IAC), which is 

comprised of a diverse group of agencies 

that have at least 90% of their financial 

disclosure filers utilizing the Integrity 

application. The IAC was established to 

advise OGE on proposed enhancements, 

improvements, and support services. 

OMB Control Number: To Be 

Determined. 

Type of Information Collection: New 

collection. 

Type of Review Request: Regular. 

Affected Public: Private citizens who 

file termination reports from such 

positions after their government service 

ends. 

Estimated Annual Number of 

Respondents: 511. 

Estimated Time per Response: 2 

minutes. 

Estimated Total Annual Burden: 17 

hours. 

Request for Comments: Public 

comment is invited specifically on the 

need for and practical utility of this 

information collection, the accuracy of 

OGE’s burden estimate, the 

enhancement of quality, utility and 

clarity of the information collected, and 

the minimization of burden (including 

the use of information technology). 

Comments received in response to this 

notice will be summarized for, and may 

be included with, the OGE request for 

OMB approval under the Paperwork 

Reduction Act. The comments will also 

become a matter of public record. 

Dated: January 18, 2024. 

Shelley K. Finlayson, 

Acting Director, U.S. Office of Government 

Ethics. 

[FR Doc. 2024–01332 Filed 1–23–24; 8:45 am] 

BILLING CODE 6345–03–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 


ddrumheller on DSK120RN23PROD with NOTICES1
4610 Federal Register / Vol. 89, No. 16 / Wednesday, January 24, 2024 / Notices 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI 

Mentored Patient-Oriented Research Study 

Section. 

Date: February 29–March 1, 2024. 

Time: 9:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Fungai Chanetsa, Ph.D., 

MPH, Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, National Institutes 

of Health, 6705 Rockledge Drive, Room 206– 

B, Bethesda, MD 20817, (301) 402–9394, 

fungai.chanetsa@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: January 18, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–01296 Filed 1–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: Ben 

Hurley at 240–669–5092, or 

benjamin.hurley@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852: tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Hybridoma Cell Lines 2A4 and 5B12 

Against Puromycin Description of 

Technology 

Protein translation is a central cellular 

function attracting increasing attention 

from cell biologists as they integrate 

gene product specific information into a 

systems view of cellular function. 

Scientists at NIAID developed the 

puromycin-specific antibodies that 

allow for the specific detection of 

puromycin-containing nascent 

polypeptides via standard 

immunofluorescence or flow cytometry. 

The resulting ribopuromycylation 

method (RPM) localizes translation in 

cells and can be applied to any PMYsensitive eukaryotic or prokaryotic cell 

to study the dynamics of protein 

synthesis at the cellular level and 

investigate translational processes. It 

can also be used in vitro or in vivo to 

measure the number of translating 

ribosomes using flow cytometry. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Broad application for studying protein 

translation. 

Competitive Advantages: 

• This technology generates antibodies 

specific for puromycin that can be 

used to localize translating ribosomes 

in all cell types. 

Development Stage: 

• Research Materials 

Inventors: Jonathan Yewdell, MD, 

Ph.D., Alexandre David, Ph.D., both of 

NIAID. 

Publications: David A. Dolan BP, 

Hickman HD, Knowlton JJ, Clavarino G, 

Pierre P, Bennink JR, Yewdell JW. 

Nuclear translation visualized by 

ribosome-bound nascent chain 

puromycylation. J Cell Biol. 2012 Apr 

2;197(1):45–57. doi: 10.1083/ 

jcb.201112145. PMID: 22472439; 

PMCID: PMC3317795. 

Also: PMID 29552591, 27385780, 

25311127, 23229864. 

Intellectual Property: HHS Reference 

No. E–003–2021. 

Licensing Contact: To license this 

technology, please contact Ben Hurley 

at 240–669–5092, or benjamin.hurley@

nih.gov, and reference E–003–2021. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Ben Hurley at 240–669–5092, or 

benjamin.hurley@nih.gov. 

Dated: January 19, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–01364 Filed 1–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Biobehavioral Processes. 

Date: February 15, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jeanne M. McCaffery, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–594–3854, jeanne.mccaffery@

nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Chemical Biology and Probes 

Study Section. 

Date: February 15–16, 2024. 

Time: 10:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 


ddrumheller on DSK120RN23PROD with NOTICES1